Home > Resources > Whitepapers > What to Look for in an Informatics Platform for Biologics R&D

What to Look for in an Informatics Platform for Biologics R&D

June 15, 2018

In silico molecular biology tools, electronic lab notebooks, and systems for registration, sample management, workflow management, and request management form the foundation of informatics for biologics R&D. The informatics platform you adopt and develop over time is an important consideration with serious consequences for both R&D and IT teams.But in the shifting landscape of biologics R&D, it can be hard to know what to look for when evaluating potential informatics platform. In this eBook, we outline the five critical platform capabilities to look for when evaluating an informatics platform for biologics R&D.

Spotlight

Talix

Talix delivers NLP powered, integrated workflow applications to improve the speed and accuracy of risk adjustment coding. Our proven applications serve health plans (first pass, second pass, and claims validation) and healthcare providers and coders (retrospective, concurrent and prospective uses) at the point of care. Talix’s sophisticated reporting and analytics capabilities provide better visibility and increased predictability of risk adjustment operations and financial performance.

OTHER WHITEPAPERS

Vaccine and Biologics Development in an Emerging Post Pandemic Landscape

whitePaper | September 20, 2022

It is clear within the global health science industry that analytical biosafety testing and advances in developing scientific technologies will play an important role in drug development’s response to the next pandemic.

Liposomal and Nanoparticle Technology at Pfizer Melbourne

whitePaper | November 22, 2022

Specializing in oncology, anti-infective and complex formulations, Pfizer Melbourne provides end-to-end services from development through to commercial manufacture of sterile dosage forms.

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

The A to Z of microarrays evolution of a revolutionary solution

whitePaper | May 27, 2023

The Human Genome Project was a monumental effort over more than a decade to determine the human DNA sequence and analyze genetic variation among individuals. The hope was that, armed with this understanding, phenotypic differences would be explainable by genetic variation, and health benefits could follow.

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Multi-Attribute Methods for Biopharmaceutical Analysis

whitePaper | December 5, 2022

The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly over the last five years.